Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) has provided an update.
CSL Limited has announced that Paul McKenzie ceased to be a director of the company on 10 February 2026, with this notice serving as his final director’s interest statement to the ASX. At the time of his departure, McKenzie held no CSL securities directly but retained indirect interests through 140,520 performance share units and 27,354 ordinary shares held in custody under the CSL Limited Performance Rights Plan, highlighting ongoing exposure to the company’s equity despite stepping down from the board.
The most recent analyst rating on (AU:CSL) stock is a Hold with a A$188.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company that develops and manufactures biopharmaceutical products, including plasma-derived and recombinant therapies, vaccines, and specialty medicines. The company focuses on treating serious and rare diseases and serves healthcare markets worldwide, with its shares listed on the Australian Securities Exchange.
Average Trading Volume: 920,389
Technical Sentiment Signal: Sell
Current Market Cap: A$87.57B
For an in-depth examination of CSL stock, go to TipRanks’ Overview page.